Therefore, we designed a prospective phase I/IIa trial called ‘Infusion of ex vivo-generated allogeneic NK cells in combination with subcutaneous (sc) IL2 in patients with acute myeloid leukemia’ (NCT04347616) to study the safety and efficacy of RNK001 cells with and without IL2 administration. Here, IL2 is linked to acute myeloid leukemia.